immuno-oncology

News

Keytruda fluffs its lines in prostate, liver cancer trials

Two phase 3 trials of Merck & Co's Keytruda in metastatic castration-resistant prostate cancer (CRPC) and advanced liver cancer have ended in failure, proving once again that cancer imm

News

Doctor in white rubber protective gloves putting adhesive bandage on young man's arm after scratch on skin or injection of vaccine. First aid. Medical, pharmacy and healthcare concept. Closeup.

Roche scores phase 3 win for subcutaneous Tecentriq, eyes fi...

Roche's Tecentriq could become the first drug in the PD-1/PD-L1 inhibitor class to be approved in a subcutaneous formulation, after the new version matched the original intravenous formulat

News

AZ, Innate's checkpoint inhibitor monalizumab flunks phase 3...

AstraZeneca has abandoned a phase 3 trial of its experimental immuno-oncology candidate monalizumab in head and neck cancer, after an interim analysis suggested it was unlikely to show a be

News

BMS' plan to move Opdivo into adjuvant RCC gets knocked back

Bristol-Myers Squibb has revealed that its checkpoint inhibitor combination of Opdivo and Yervoy failed a phase 3 trial as adjuvant (post-surgery) therapy for renal cell carcinoma (RCC), th

News

Opdualag off to a flying start, says BMS CEO

Bristol-Myers Squibb's new immune checkpoint inhibitor combination Opdualag has only been on the US market for a few weeks but is already off to a "great start", according to chief executiv

News